Chinese Journal of Antituberculosis ›› 2022, Vol. 44 ›› Issue (11): 1126-1134.doi: 10.19982/j.issn.1000-6621.20220224
• Original Articles • Previous Articles Next Articles
Wu Kunyang1, Lu Yewei2, Zhang Mingwu1, Zhu Yelei1, Li Xiangchen2, Pan Junhang1, Wang Xiaomeng1, Wang Wei3, Jiang Minmin4, Peng Xiaojun2, Wang Weixin2, Gao Junshun2, Liu Zhengwei1()
Received:
2022-06-08
Online:
2022-11-10
Published:
2022-11-03
Contact:
Liu Zhengwei
E-mail:zhwliu@cdc.zj.cn
Supported by:
CLC Number:
Wu Kunyang, Lu Yewei, Zhang Mingwu, Zhu Yelei, Li Xiangchen, Pan Junhang, Wang Xiaomeng, Wang Wei, Jiang Minmin, Peng Xiaojun, Wang Weixin, Gao Junshun, Liu Zhengwei. Analysis on characteristic of drug resistance-associated gene mutations and the correlation with genotypes among Mycobacterium tuberculosis isolates in Zhejiang Province[J]. Chinese Journal of Antituberculosis, 2022, 44(11): 1126-1134. doi: 10.19982/j.issn.1000-6621.20220224
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20220224
药品 | 耐药菌株株数 | 耐药率(%) | 耐药基因 | 突变菌株数 | 突变率(%) |
---|---|---|---|---|---|
异烟肼 | 75 | 9.3 | katG | 54 | 72.0 |
inhA | 14 | 18.7 | |||
inhA+katG | 2 | 2.7 | |||
ahpC+katG | 2 | 2.7 | |||
ahpC | 2 | 2.7 | |||
ahpC+inhA+katG | 1 | 1.3 | |||
利福平 | 28 | 3.5 | rpoB | 26 | 92.9 |
rpoB+rpoC | 2 | 7.1 | |||
乙胺丁醇 | 16 | 2.0 | embB | 14 | 87.5 |
embA+embB | 1 | 6.3 | |||
embA | 1 | 6.3 | |||
吡嗪酰胺 | 12 | 1.5 | pncA | 12 | 100.0 |
链霉素 | 55 | 6.8 | rpsL | 40 | 72.7 |
rrs | 12 | 21.8 | |||
gid | 2 | 3.6 | |||
gid+rrs | 1 | 1.8 | |||
氟喹诺酮类 | 41 | 5.1 | gyrA | 36 | 87.8 |
gyrB | 4 | 9.8 | |||
gyrA+gyrB | 1 | 2.4 | |||
阿米卡星 | 3 | 0.4 | rrs | 3 | 100.0 |
卡那霉素 | 4 | 0.5 | rrs | 3 | 75.0 |
eis | 1 | 25.0 | |||
卷曲霉素 | 3 | 0.4 | rrs | 3 | 100.0 |
药品 | 耐药菌株株数 | 耐药率(%) | 耐药基因 | 突变菌株数 | 突变率(%) |
乙硫异烟胺 | 20 | 2.5 | inhA | 16 | 80.0 |
ethA | 3 | 15.0 | |||
ethA+inhA | 1 | 5.0 | |||
对氨基水杨酸 | 8 | 1.0 | thyA | 7 | 87.5 |
folC | 1 | 12.5 |
药品 | 耐药菌 株数 | 耐药率 (%) | 突变类型 | 突变菌 株数 | 突变率 (%) | 平均测序 深度 | 平均突变频率 (%) |
---|---|---|---|---|---|---|---|
异烟肼 | 75 | 9.3 | katG-315-S/T | 45 | 60.0 | 457 | 99.3 |
inhA-15-C/T | 13 | 17.3 | 423 | 94.5 | |||
ahpC启动子-48-G/A | 4 | 5.3 | 572 | 96.8 | |||
其他 | 20 | 26.6 | 375 | 95.5 | |||
利福平 | 28 | 3.5 | rpoB-450-S/L | 16 | 57.1 | 385 | 97.7 |
rpoB-452-L/P | 4 | 14.3 | 393 | 82.5 | |||
rpoB-430-L/P | 4 | 14.3 | 329 | 100.0 | |||
其他 | 9 | 32.1 | 470 | 99.9 | |||
乙胺丁醇 | 16 | 2.0 | embB-306-M/V | 7 | 43.8 | 396 | 95.5 |
embB-306-M/I | 2 | 12.5 | 381 | 100.0 | |||
embB-354-D/A | 2 | 12.5 | 491 | 99.9 | |||
其他 | 6 | 37.5 | 483 | 90.6 | |||
吡嗪酰胺 | 12 | 1.5 | - | - | - | 526 | 99.6 |
链霉素 | 55 | 6.8 | rpsL-43-K/R | 36 | 65.5 | 569 | 99.8 |
rrs-514-A/C | 6 | 10.9 | 418 | 97.1 | |||
rpsL-88-K/R | 3 | 5.5 | 473 | 100.0 | |||
其他 | 8 | 14.6 | 329 | 64.0 | |||
氟喹诺酮类 | 41 | 5.1 | gyrA-94-D/G | 15 | 36.6 | 473 | 92.9 |
gyrA-90-A/V | 12 | 29.3 | 491 | 94.5 | |||
gyrA-94-D/N | 7 | 17.1 | 572 | 98.7 | |||
其他 | 10 | 24.4 | 495 | 65.4 | |||
阿米卡星 | 3 | 0.4 | rrs-1402-C/A | 3 | 3/3 | 249 | 21.7 |
rrs-1484-G/T | 2 | 2/3 | 290 | 19.3 | |||
卡那霉素 | 4 | 0.5 | rrs-1402-C/A | 3 | 3/4 | 249 | 21.7 |
rrs-1484-G/T | 2 | 2/4 | 290 | 19.3 | |||
eis启动子-10-G/A | 1 | 1/4 | 547 | 100.0 | |||
卷曲霉素 | 3 | 0.4 | rrs-1402-C/A | 3 | 3/3 | 249 | 21.7 |
rrs-1484-G/T | 2 | 2/3 | 290 | 19.3 | |||
乙硫异烟胺 | 20 | 2.5 | inhA-15-C/T | 13 | 65.0 | 423 | 94.5 |
其他 | 8 | 40.0 | 469 | 96.6 | |||
对氨基水杨酸 | 8 | 1.0 | thyA-75-H/N | 7 | 7/8 | 736 | 99.8 |
folC-150-S/G | 1 | 1/8 | 613 | 97.4 |
突变位点 | 表型药敏试验结果 | 不一致株数 | 比例(%) | 突变菌株数 | 不一致率(%) |
---|---|---|---|---|---|
katG-315-S/T | 敏感 | 5 | 23.8 | 43 | 11.6 |
ahpC启动子-48-G/A | 敏感 | 3 | 14.3 | 4 | 3/4 |
inhA-15-C/T | 敏感 | 2 | 9.5 | 12 | 16.7 |
katG-110-A/V | 敏感 | 1 | 4.8 | 2 | - |
katG-127-Q/P | 敏感 | 1 | 4.8 | 1 | - |
katG-258-N/S | 敏感 | 1 | 4.8 | 1 | - |
katG-335-I/V | 敏感 | 1 | 4.8 | 1 | - |
katG-337-Y/C | 敏感 | 1 | 4.8 | 1 | - |
katG-607-E/K | 敏感 | 1 | 4.8 | 1 | - |
野生型 | 耐药 | 7 | 33.3 | - | - |
[1] | World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization, 2021. |
[2] |
陈松华, 吴蓓蓓, 柳正卫, 等. 浙江省结核病耐药状况分析. 预防医学, 2016, 28(8): 757-761,765. doi: 10.19485/j.cnki.issn1007-0931.2016.08.001.
doi: 10.19485/j.cnki.issn1007-0931.2016.08.001 |
[3] |
Kizny Gordon A, Marais B, Walker TM, et al. Clinical and public health utility of Mycobacterium tuberculosis whole genome sequencing. Int J Infect Dis, 2021, 113 Suppl 1: S40-S42. doi: 10.1016/j.ijid.2021.02.114.
doi: 10.1016/j.ijid.2021.02.114 pmid: 33716192 |
[4] |
张洁, 任怡宣, 潘丽萍, 等. 全基因组测序在结核分枝杆菌研究中的应用. 中国防痨杂志, 2020, 42(7): 737-740. doi: 10.3969/j.issn.1000-6621.2020.07.017.
doi: 10.3969/j.issn.1000-6621.2020.07.017 |
[5] |
Meehan CJ, Goig GA, Kohl TA, et al. Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues. Nat Rev Microbiol, 2019, 17(9): 533-545. doi: 10.1038/s41579-019-0214-5.
doi: 10.1038/s41579-019-0214-5 pmid: 31209399 |
[6] |
Cohen KA, Manson AL, Desjardins CA, et al. Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: progress, promise, and challenges. Genome Med, 2019, 11(1):45. doi: 10.1186/s13073-019-0660-8.
doi: 10.1186/s13073-019-0660-8 URL |
[7] | 中国防痨协会. 结核病实验室检验规程. 北京: 人民卫生出版社, 2015:59-65. |
[8] |
Chen S, Zhou Y, Chen Y, et al. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics, 2018, 34(17):i884-i890. doi: 10.1093/bioinformatics/bty560.
doi: 10.1093/bioinformatics/bty560 URL |
[9] |
Phelan JE, O’Sullivan DM, Machado D, et al. Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs. Genome Med, 2019, 11(1):41. doi: 10.1186/s13073-019-0650-x.
doi: 10.1186/s13073-019-0650-x pmid: 31234910 |
[10] | World Health Organization. GLASS whole-genome sequencing for surveillance of antimicrobial resistance. Geneva: World Health Organization, 2020. |
[11] |
Walker TM, Kohl TA, Omar SV, et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis, 2015, 15(10):1193-1202. doi: 10.1016/S1473-3099(15)00062-6.
doi: 10.1016/S1473-3099(15)00062-6 URL |
[12] |
Chen X, He G, Wang S, et al. Evaluation of Whole-Genome Sequence Method to Diagnose Resistance of 13 Anti-tuberculosis Drugs and Characterize Resistance Genes in Clinical Multi-Drug Resistance Mycobacterium tuberculosis Isolates From China. Front Microbiol, 2019, 10:1741. doi: 10.3389/fmicb.2019.01741.
doi: 10.3389/fmicb.2019.01741 URL |
[13] | World Health Organization. Target product profile for next-generation drug-susceptibility testing at peripheral centres. Geneva: World Health Organization, 2021. |
[14] |
Hillemann D, Rüsch-Gerdes S, Boehme C, et al. Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system. J Clin Microbiol, 2011, 49(4):1202-1205. doi: 10.1128/JCM.02268-10.
doi: 10.1128/JCM.02268-10 pmid: 21270230 |
[15] |
Meaza A, Kebede A, Yaregal Z, et al. Evaluation of genotype MTBDRplus VER 2.0 line probe assay for the detection of MDR-TB in smear positive and negative sputum samples. BMC Infect Dis, 2017, 17(1):280. doi: 10.1186/s12879-017-2389-6.
doi: 10.1186/s12879-017-2389-6 pmid: 28415989 |
[16] |
Jian J, Yang X, Yang J, et al. Evaluation of the GenoType MTBDRplus and MTBDRsl for the detection of drug-resistant Mycobacterium tuberculosis on isolates from Beijing, China. Infect Drug Resist, 2018, 11:1627-1634. doi: 10.2147/IDR.S176609.
doi: 10.2147/IDR.S176609 URL |
[17] |
罗丹, 覃慧芳, 叶婧, 等. 广西壮族自治区结核分枝杆菌耐药基因突变特征及其与基因型的相关性分析. 中国防痨杂志, 2021, 43(6): 596-601. doi: 10.3969/j.issn.1000-6621.2021.06.013.
doi: 10.3969/j.issn.1000-6621.2021.06.013 |
[18] |
洪创跃, 杨婷婷, 李金莉, 等. 深圳市耐多药结核分枝杆菌耐药基因突变特征分析. 中国防痨杂志, 2020, 42(6): 583-589. doi: 10.3969/j.issn.1000-6621.2020.06.009.
doi: 10.3969/j.issn.1000-6621.2020.06.009 |
[19] |
高敏, 杨婷婷, 李桂莲, 等. 基于全基因组测序的我国耐多药结核分枝杆菌耐药突变特征分析. 中华流行病学杂志, 2020, 41(5): 770-775. doi: 10.3760/cma.j.cn112338-20191111-00800.
doi: 10.3760/cma.j.cn112338-20191111-00800 |
[20] |
田丽, 周伟, 黄星, 等. 中国异烟肼耐药结核分枝杆菌基因突变特征分析. 中国防痨杂志, 2022, 44(4): 354-361. doi: 10.19982/j.issn.1000-6621.20210573.
doi: 10.19982/j.issn.1000-6621.20210573 |
[21] |
Lempens P, Meehan CJ, Vandelannoote K, et al. Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations. Sci Rep, 2018, 8(1):3246. doi: 10.1038/s41598-018-21378-x.
doi: 10.1038/s41598-018-21378-x URL |
[22] |
Zhang D, Liu B, Wang Y, et al. Rapid molecular screening for multidrug-resistant tuberculosis in a resource-limited region of China. Trop Med Int Health, 2014, 19(10):1259-1266. doi: 10.1111/tmi.12359.
doi: 10.1111/tmi.12359 pmid: 25040060 |
[23] |
Ye M, Yuan W, Molaeipour L, et al. Antibiotic heteroresistance in Mycobacterium tuberculosis isolates: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob, 2021, 20(1):73. doi: 10.1186/s12941-021-00478-z.
doi: 10.1186/s12941-021-00478-z URL |
[24] |
Javed H, Bakuła Z, Pleń M, et al. Evaluation of Genotype MTBDRplus and MTBDRsl Assays for Rapid Detection of Drug Resistance in Extensively Drug-Resistant Mycobacterium tuberculosis Isolates in Pakistan. Front Microbiol, 2018, 9:2265. doi: 10.3389/fmicb.2018.02265.
doi: 10.3389/fmicb.2018.02265 URL |
[25] |
Dantas NGT, Suffys PN, Carvalho WDS, et al. Correlation between the BACTEC MGIT 960 culture system with Genotype MTBDRplus and TB-SPRINT in multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil. Mem Inst Oswaldo Cruz, 2017, 112(11):769-774. doi: 10.1590/0074-02760170062.
doi: 10.1590/0074-02760170062 URL |
[26] |
Li D, Hu Y, Werngren J, et al. Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resis-tant Tuberculosis in China. Antimicrob Agents Chemother, 2016, 60(9):5159-5166. doi: 10.1128/AAC.02687-15.
doi: 10.1128/AAC.02687-15 URL |
[27] |
Huang H, Ding N, Yang T, et al. Cross-sectional Whole-genome Sequencing and Epidemiological Study of Multidrug-resistant Mycobacterium tuberculosis in China. Clin Infect Dis, 2019, 69(3):405-413. doi: 10.1093/cid/ciy883.
doi: 10.1093/cid/ciy883 URL |
[1] | National Clinical Research Centre for Infectious Disease/The Third People’s Hospital of Shenzhen, Peking University Shenzhen Hospital, Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Shenzhen Key Laboratory of Inflammatory and Immune Diseases. Expert consensus on diagnosis and treatment of latent tuberculosis infection in patients with rheumatic diseases [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 869-879. |
[2] | Wang Yuxiang, Chen Qiuqi, Yu Xinxin, Zhan Senlin, Zhang Peize, Deng Guofang. 3HP regimen in the treatment of rheumatic diseases complicated with Mycobacterium tuberculosis latent infection:a prospective study [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 906-910. |
[3] | Xie Jingyi, Zou Ruifeng, Chen Yulan, Chen Yong, Liu Dongzhou, Hong Xiaoping. Analysis of clinical features and peripheral lymphocyte subsets of systemic lupus erythematosus patients complicated with tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 911-916. |
[4] | Cheng Xiao, Chen Zhe, Jiao Xuefeng, Yang Nan, Diao Sha, Ni Xiaofeng, Liu Zheng, He Siyi, Zeng Linan, Wan Chaomin, Kang Deying, Wu Bin, Ying Binwu, Zhang Hui, Zhao Rongsheng, Zhang Lingli. Efficacy and safety of recombinant Mycobacterium tuberculosis fusion proteins (EC) for the diagnosis of Mycobacterium tuberculosis infection: A system review [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 917-926. |
[5] | Wu Wenqi, Zhong Jianqiu, He Juan, Deng Guofang, Wang Qingwen. The research progress of the reactivation of latent tuberculosis infection in patients with rheumatic diseases [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 954-959. |
[6] | Dong Xiaowei, Guo Huixin, Zhang Chenchen, Wang Jiawen, He Junlei, Li Guanhai, Li Jianwei, Wen Wenpei. Application value of two-step detection of Mycobacterium tuberculosis infection screening in schools [J]. Chinese Journal of Antituberculosis, 2022, 44(8): 802-807. |
[7] | Li Yinhong, Liu Fanglin, Lu Zhenhui, Jiang Xin. Study on the mechanism of Oridonin against pathological damage of tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(8): 849-854. |
[8] | XIA Hui, ZHENG Yang, SONG Yuan-yuan. Interpretation of the Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis complex issued by World Health Organization [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 641-645. |
[9] | LIU Hai-ting, LI Dong-shuo, ZHANG Lei, WANG Ning, WANG Bin, DING Yang-ming, YAO Rong, LU Yu. A preliminary study on the synergy and mechanism of pyrifazimine and bedaquiline [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 646-653. |
[10] | DAI Xiao-wei, WANG Nen-han, CHEN Shuang-shuang, YANG Xin-yu, TIAN Li-li, CHEN Hong, ZHANG Hong-tai, LI Chuan-you. Assessing next-generation sequencing for Mycobacterium tuberculosis diagnosis in clinical sputum samples [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 669-679. |
[11] | JIA Hong-yan, DONG Jing, ZHANG Zong-de, PAN Li-ping. Progress and clinical application of immunological detection technology for Mycobacterium tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 720-726. |
[12] | WANG Ning, ZHENG Lu-yao, MENG Xiu-juan, LIU Hai-ting, DING Yang-ming, YAO Rong, GUO Shao-chen, LU Yu. Distribution characteristics of N-acetyltransferase-2 genotypes and comparison methods of different genotyping in Chinese population [J]. Chinese Journal of Antituberculosis, 2022, 44(6): 625-634. |
[13] | HE Yi-jun, CAO Xue-fang, GAO Lei. Interpretation of the Procedure of tuberculin skin test-interferon-gamma release assay two-step testing [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 438-441. |
[14] | DAI Guang-ming, WANG fen, CAO Ting-ming, CHU Hong-qian, HUANG Hai-rong, SUN Zhao-gang. Study on efficiency of Mycobacterium tuberculosis detection by real-time quantitative PCR with different clinical sample types and the improvement by grinding specimen with glass beads [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 450-454. |
[15] | SUN Qing, LIAO Xin-lei, WANG Chen-qian, JIANG Guang-lu, DONG Ling-ling, WANG Fen, ZHAO Li-ping, HUANG Hai-rong, WANG Gui-rong. Characterization of rifampin resistance determining region mutations in tuberculosis patients with GeneXpert MTB/RIF positive RNA polymerase β subunit gene mutation [J]. Chinese Journal of Antituberculosis, 2022, 44(4): 349-353. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||